Table 2.
Subcutaneous adipose tissue inflammation and morphology associated with visceral adipose tissue mass.
| VAT mass, L | VAT mass, La | |||
|---|---|---|---|---|
| β (95% CI) | p-value | β (95% CI) | p-value | |
| SAT Adipocyte size | 0.20 (− 0.76 to 1.15) | 0.67 | − 0.27 (− 1.17 to 0.62) | 0.53 |
| SAT PPAR-γ | − 0.29 (− 0.81 to 0.22) | 0.24 | 0.04 (− 0.65 to 0.72) | 0.90 |
| SAT FAS | − 1.23 (− 1.67 to − 0.80) | < 0.001 | − 1.33 (− 1.93 to − 0.72) | < 0.001 |
| SAT SCD1 | − 0.86 (− 1.56 to − 0.17) | 0.02 | − 0.78 (− 1.75 to 0.20) | 0.11 |
| SAT HIF-1α | 0.77 (0.34 to 1.21) | 0.002 | 0.52 (0.13 to 0.92) | 0.01 |
| SAT VEGFA | − 0.40 (− 0.88 to 0.08) | 0.10 | − 0.06 (− 0.50 to 0.39) | 0.80 |
| SAT ESR1 | − 0.37 (− 0.80 to 0.07) | 0.09 | − 0.03 (− 0.44 to 0.38) | 0.88 |
| SAT AdipoQ | − 0.52 (− 0.92 to − 0.12) | 0.01 | − 0.19 (− 0.61 to 0.24) | 0.36 |
| SAT CD163+ cells | 0.13 (0.07 to 0.20) | < 0.001 | 0.09 (0.00 to 0.17) | 0.04 |
| SAT CD68+ cells | 0.16 (− 0.04 to 0.35) | 0.10 | 0.14 (− 0.03 to 0.30) | 0.10 |
| SAT CD3+ cells | 0.65 (0.15 to 1.15) | 0.01 | 0.45 (0.03 to 0.86) | 0.04 |
| SAT CD20+ cells | 0.86 (0.28 to 1.44) | 0.005 | 0.65 (0.11 to 1.19) | 0.02 |
| SAT PcF | 0.17 (0.04 to 0.30) | 0.01 | 0.10 (− 0.04 to 0.24) | 0.14 |
| SAT IL-6 mRNA | 0.75 (0.19 to 1.30) | 0.01 | 0.50 (0.03 to 0.96) | 0.04 |
| SAT IL-18 mRNA | 4.34 (2.71 to 5.98) | < 0.001 | 3.28 (1.23 to 5.33) | 0.003 |
| SAT TNF-α mRNA | 0.59 (0.15 to 1.04) | 0.01 | 0.40 (0.03 to 0.77) | 0.03 |
| SAT MCP-1 mRNA | 1.24 (0.09 to 2.39) | 0.04 | 0.93 (0.04 to 1.81) | 0.04 |
SAT subcutaneous adipose tissue, VAT visceral adipose tissue, PPAR Peroxisome proliferator activated receptor, FAS fatty-acid synthase, SCD Stearoyl-CoA desaturase, HIF Hypoxia-inducible factor, VEGFA vascular endothelial growth factor, ESR1 estrogen receptor 1, AdipoQ adiponectin, CD cluster of differentiation, PcF pericellular fibrosis, IL interleukin, TNF tumor necrosis factor, MCP Monocyte Chemoattractant Protein. N = 26.
aModel corrected for total fat mass.